Return to homepagePandemic Pact

Towards development of a potent antiviral against the SARS CoV2 by targeting the interaction between nucleocapsid protein and viral RNA.

Grant number: IPA/2020/000233

Grant search

Key facts

  • Disease

    COVID-19

  • Funder

    SERB India

  • Principal Investigator

    Dr. Milan Surjit

  • Research Location

    India

  • Lead Research Institution

    Translational Health Science and Technology Institute Faridabad, Haryana

  • Research Priority Alignment

    N/A

  • Research Category

    Therapeutics research, development and implementation

  • Research Subcategory

    Pre-clinical studies

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

New or repurposed antivirals against valid viral targets, viricidal coatings

Publicationslinked via Europe PMC

Last Updated:2 days ago

View all publications at Europe PMC

RNA-Protein Interaction Analysis of SARS-CoV-2 5' and 3' Untranslated Regions Reveals a Role of Lysosome-Associated Membrane Protein-2a during Viral Infection.